Foamix Pharmaceuticals Ltd. - Ordinary Shares (FOMX): Price and Financial Metrics
FOMX Stock Summary
- FOMX's price/sales ratio is 247.01; that's higher than the P/S ratio of 98.81% of US stocks.
- With a year-over-year growth in debt of 671.55%, NA's debt growth rate surpasses 96.43% of about US stocks.
- Revenue growth over the past 12 months for NA comes in at -61.03%, a number that bests merely 2.48% of the US stocks we're tracking.
- Stocks that are quantitatively similar to FOMX, based on their financial statements, market capitalization, and price volatility, are ETON, GERN, RESN, TROV, and VTVT.
FOMX Stock Price Chart Interactive Chart >
FOMX Price/Volume Stats
|Current price||$2.99||52-week high||$4.84|
|Prev. close||$3.24||52-week low||$1.97|
|Day high||$3.44||Avg. volume||596,231|
|50-day MA||$3.94||Dividend yield||N/A|
|200-day MA||$3.16||Market Cap||184.13M|
Foamix Pharmaceuticals Ltd. - Ordinary Shares (FOMX) Company Bio
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. The company was founded in 2003 and is based in Rehovot, Israel.